Optimize formulation of VSA adjuvant
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93022C00033
- Awardee
-
Adjuvax LLC UEI EGVNJG3GMEL7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $600,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20221 · Posted Jul 12, 2021
- Contract value 100% obligated
- $600,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 9 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35226, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $600,000 |
About this award
Adjuvax LLC has been awarded a $600,000 firm fixed price definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to optimize the formulation of a virus-like particle adjuvant under a Small Business Innovation Research solicitation. The solicitation sought proposals across technical topics aligned with NIH and CDC missions to develop medical technologies and other solutions to advance public health. This opportunity was set aside for total small business participation. Work will be performed by Adjuvax LLC in Birmingham, Alabama from July 2022 through July 2024 to support the National Institute of Allergy and Infectious Diseases' goals in developing adjuvants and vaccines.
Quick answers
Who was awarded contract 75N93022C00033?
75N93022C00033 was awarded to Adjuvax LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 5, 2022.
How much is contract 75N93022C00033 worth?
The government has obligated $600,000 on 75N93022C00033.
Was contract 75N93022C00033 competed?
The extent of competition for 75N93022C00033 was full and open competition after exclusion of sources. The government received 9 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award